Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2021 Aug 9;17(8):e1009802. doi: 10.1371/journal.ppat.1009802

Modern Acinetobacter baumannii clinical isolates replicate inside spacious vacuoles and egress from macrophages

Gabriela Sycz 1,#, Gisela Di Venanzio 1,#, Jesus S Distel 1, Mariana G Sartorio 1, Nguyen-Hung Le 1, Nichollas E Scott 2, Wandy L Beatty 1, Mario F Feldman 1,*
Editor: David S Weiss3
PMCID: PMC8376066  PMID: 34370792

Abstract

Multidrug-resistant Acinetobacter baumannii infections are increasing at alarming rates. Therefore, novel antibiotic-sparing treatments to combat these A. baumannii infections are urgently needed. The development of these interventions would benefit from a better understanding of this bacterium’s pathobiology, which remains poorly understood. A. baumannii is regarded as an extracellular opportunistic pathogen. However, research on Acinetobacter has largely focused on common lab strains, such as ATCC 19606, that have been isolated several decades ago. These strains exhibit reduced virulence when compared to recently isolated clinical strains. In this work, we demonstrate that, unlike ATCC 19606, several modern A. baumannii clinical isolates, including the recent clinical urinary isolate UPAB1, persist and replicate inside macrophages within spacious vacuoles. We show that intracellular replication of UPAB1 is dependent on a functional type I secretion system (T1SS) and pAB5, a large conjugative plasmid that controls the expression of several chromosomally-encoded genes. Finally, we show that UPAB1 escapes from the infected macrophages by a lytic process. To our knowledge, this is the first report of intracellular growth and replication of A. baumannii. We suggest that intracellular replication within macrophages may contribute to evasion of the immune response, dissemination, and antibiotic tolerance of A. baumannii.

Author summary

Acinetobacter baumannii is a nosocomial pathogen that causes multiple types of infection. This bacterium has an alarming predisposition to acquire multi-drug resistance, and infections associated with these strains are linked to greater morbidity and mortality. Therefore, novel antibiotic-sparing treatments to combat these A. baumannii infections are urgently needed. The development of these interventions would benefit from a better understanding of the mechanisms employed by A. baumannii to cause infection. A. baumannii is regarded as an extracellular opportunistic pathogen. However, research on Acinetobacter has largely focused on common lab strains that have been isolated several decades ago. These strains exhibit reduced virulence when compared to recently isolated clinical strains. In this work, we demonstrate that a subset of modern A. baumannii clinical isolates persist and replicate inside macrophages within spacious vacuoles, and identify bacterial factors involved in the process. We propose that replication inside macrophages may contribute to the evasion of the immune response and bacterial dissemination. Antibiotics cannot penetrate the macrophages, and therefore our findings contribute to explain the extremely high tolerance of A. baumannii to antibiotics. Our work opens new avenues for the development of novel therapeutic interventions against this worrisome human pathogen.

Introduction

Infections caused by the bacterial pathogen Acinetobacter baumannii are a global public health risk since multidrug resistance (MDR) increasingly limits effective therapeutic interventions[1,2]. The emerging success of this pathogen has led the World Health Organization (WHO) and the CDC to categorize carbapenem-resistant A. baumannii as a top priority for the research and development of new antibiotics[3,4]. However, compared to other opportunistic pathogens, our knowledge about the pathobiology of Acinetobacter is rather limited.

Research on Acinetobacter has largely focused on common lab strains that have been “lab-domesticated” over ~50 years. These non-MDR strains exhibit reduced virulence when compared to recently isolated clinical strains, indicating that classical lab strains lack virulence factors expressed by current-day strains[5,6]. Consequently, little is known about the virulence factors and molecular pathways governing modern A. baumannii infections. Although A. baumannii is best known as a respiratory pathogen, infection of various anatomical sites is also common. For example, urinary tract infections (UTI) account for about ~20% of A. baumannii infections worldwide[5]. We recently developed a murine model of A. baumannii catheter-associated urinary tract infection (CAUTI)[5]. Using this model, we compared the behavior of two urinary A. baumannii isolates, ATCC19606 (19606) and UPAB1. 19606 is a urinary isolate obtained in 1967, and it has been routinely used to study A. baumannii virulence. UPAB1 is a modern MDR UTI isolate, collected from a female patient in 2016. We demonstrated that, unlike 19606, which was rapidly cleared from infected mice, UPAB1 was able to establish early implant and bladder colonization[5]. These findings suggested that “old” and “new” strains have a different repertoire of virulence or fitness factors, which can influence the outcome of the infection. Interestingly, UPAB1 carries a large conjugative plasmid (LCP), pAB5, which controls the expression of multiple virulence factors. Remarkably, pAB5 impacts the pathogenicity of UPAB1 in the CAUTI and acute pneumonia murine models[5].

A few reports have suggested that classical A. baumannii strains are able to persist within epithelial cells. It has been suggested that the intracellular bacterial cells are contained by membrane-bound vacuoles, likely of autophagic origin, and subsequently eliminated by the intracellular vesicular pathway[710]. In this work, we demonstrate that unlike 19606, several modern A. baumannii clinical isolates, including UPAB1, persist and, remarkably, replicate inside macrophages within spacious vacuoles containing up to more than 30 bacteria. We show that intracellular replication of UPAB1 is dependent on pAB5 and a functional Type I Secretion System (T1SS). Finally, we also show that UPAB1 escapes from the infected macrophages by a lytic process. To the best of our knowledge, this is the first report of intracellular growth and replication of A. baumannii.

Results

UPAB1 but not 19606 replicates in spacious intracellular vacuoles within macrophages

Macrophages play an important role in early host defense against A. baumannii. Indeed, depletion of macrophages enhances sepsis and severity of A. baumannii infection [11]. Macrophages can efficiently control the replication of A. baumannii and kill the most common lab strains, such as ATCC 17978 and 19606, which have been isolated more than half a century ago. However, whether modern clinical isolates can be efficiently phagocytosed and eliminated by macrophages has not been investigated. To this end, we tested the ability of the modern A. baumannii isolate UPAB1 to resist macrophage-killing. J774A.1 macrophages were infected at an MOI of 10 and visualized by TEM. We found that UPAB1-infected J774A.1 macrophages possessed spacious vacuoles containing up to 15 bacteria per vacuole (Fig 1A). Hereafter, we refer to these structures as A. baumannii-Containing Vacuoles (ACVs). A double membrane was visible in some of the ACVs, which is compatible with an autophagic origin (Fig 1B, right panel). This result is in agreement with previous reports showing that A. baumannii lab strains are contained within autophagic ACVs in epithelial cells [12]. CFU enumeration of intracellular bacteria (Fig 2A) showed that UPAB1 can replicate intracellularly between 2 to 6 h p.i. In contrast, the lab strain 19606 was efficiently eliminated and no intracellular replication was detected (Fig 2A). Visualization of intracellular bacteria by confocal microscopy demonstrated the presence of small ACVs at 2.5 h p.i and some large ACVs, containing more than 20 bacteria per vacuole, at 5 and 7 h p.i. (Figs 2B and S1). Indeed, the number of bacteria per ACV increased with time (Figs 2B, 2C and S1 and S2). We were able to detect vacuoles with up to 30 to 40 intracellular UPAB1 between 5 to 7 h p.i. Almost no intracellular bacteria were observed in macrophages infected with 19606 at similar time points (Figs 2B, right lower panel, and S2). Together, these experiments demonstrate that UPAB1 is able to infect, persist and replicate intracellularly in J774A.1 macrophages.

Fig 1. UPAB1 resides in spacious vacuoles within macrophages.

Fig 1

Transmission electron microscopic images of J774A.1 macrophages infected with UPAB1 (A) at 5 (left panel) and 7 h p.i. (right panel) Bars: 2 μm. (B) The UPAB1 containing vacuole can have a single (left panel, white arrow) or double membrane (right panel, white arrow). Bars: 500 nm.

Fig 2. UPAB1 but not 19606 replicates in macrophages.

Fig 2

(A) J774A.1 macrophages were infected with the indicated strains, and after phagocytosis, extracellular bacteria were eliminated with antibiotics. After different time points, total numbers of intracellular CFU were determined. *p < 0.05. (B) Representative images of infected cells at the indicated time points. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Insets show a higher magnification of the area indicated by the white box. Individual channels are presented in S3 Fig. Bars: 20 μm. (C) Quantification of bacteria per vacuole at different times p.i. Each symbol represents an individual vacuole, horizontal line represents the median. At least 200 infected cells were analyzed for each time point for three independent experiments.

UPAB1 ACVs are LC3-negative

Autophagy is a well-established intracellular mechanism by which the eukaryotic cells eliminate unwanted components, including invading pathogens[13]. However, some intracellular pathogens are able to grow in vacuoles with autophagic features, like Serratia marcescens and Coxiella burnetii [14,15]. Several studies employing non-replicative A. baumannii lab strains have proposed that upon infection, the autophagic pathway is activated in host cells, leading to an accumulation of LC3-positive vacuoles[8]. Although many alternative molecular pathways have been described in the autophagic process, one common characteristic of the autophagic vacuoles is a double membrane and the presence of the protein LC3 in both membranes[16]. As some of the UPAB1-containing vacuoles exhibited a double membrane, we investigated if these vacuoles contained LC3 (S3 Fig). Uninfected macrophages showed a smooth cytoplasmic distribution of LC3, characteristic of non-autophagic processes (S3A Fig). Serratia marcescens RM66262 vacuoles were LC3-positive at 2 h p.i. (S3B Fig), as previously described[14]. However, no LC3-positive vacuoles (S3C Fig) were visualized in cells infected with UPAB1 at all the observed time points (1, 2.5 and 5 h p.i.), suggesting that replicative ACVs follow a non-canonical intracellular pathway.

UPAB1 also replicates in THP-1 cells and bone-marrow-derived macrophages (BMDM)

Large ACVs were also observed in human THP-1 cells (Figs 3, left panel and S4) and, remarkably, in murine BMDM (Figs 3, right panel and S2 and S4), indicating that intracellular replication of UPAB1 is a phenomenon that occurs in multiple host cells and does not depend on a permissive host cell. For the remainder of the study, we will employ J774A.1 macrophages as host cells.

Fig 3. UPAB1 replicates in multiple host cell lines.

Fig 3

Representative images of infected THP-1 (left panels) or BMDM (right panels) cells at 5 h p.i. Samples were stained for cell nuclei (grey), actin (magenta) and UPAB1 GFP (cyan). Insets show a higher magnification of the area indicated by the white box. Individual channels are presented in S4 Fig. Bars: 20 μm.

A subset of MDR clinical isolates replicate inside macrophages

Lab-domesticated strains generally exhibit reduced virulence in animal models when compared to recently isolated clinical strains, a possible indication that classical lab strains lack virulence factors expressed by current-day strains[17]. We next tested if other recent MDR clinical isolates were able to replicate in macrophages (Fig 4). Although at different rates, many of these clinical isolates also replicated in J774A.1 macrophages (Fig 4A). These strains were also contained in large ACVs (Figs 4B and S5), demonstrating that intracellular replication is not a unique feature of UPAB1. We found that AbCAN2[18], a recent bone isolate was not able to replicate and was quickly eliminated by J774A.1 macrophages. These experiments demonstrate that a subset of modern clinical isolates replicate within macrophages.

Fig 4. Recent clinical isolates replicate in macrophages.

Fig 4

(A) J774A.1 macrophages were infected with the indicated strains and, after phagocytosis, extracellular bacteria were eliminated with antibiotics. After different time points, total numbers of intracellular CFU were determined. Data represent mean and standard deviation values for 3 independent experiments. (B) Representative images of infected cells with the indicated strains. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Insets show a higher magnification of the area indicated by the white box. Individual channels are presented in S5 Fig. Bars: 20 μm.

UPAB1 escapes the macrophages by a lytic process

Our results show that intracellular CFUs of UPAB1 in J774A.1 peak at 4–6 h p.i., and then decrease at later time points (Fig 2A). This decline may be the result of bacterial death inside the vacuoles. Alternatively, the reduction in the CFUs of intracellular bacteria could reflect the egress of bacteria from the infected macrophage to the extracellular media. To investigate these hypotheses, we carried out a modified antibiotic protection assay. In this assay, antibiotics were added 1 h p.i. to eliminate extracellular non-phagocytosed bacteria. At different time points, the antibiotic-containing medium was replaced by fresh cell culture medium without antibiotics. After a 20 min incubation, the culture supernatants from each well were recovered and the number of released bacteria were quantified. The ratio of released bacteria in relation to the number of intracellular bacteria corresponding to each time interval is shown in Fig 5A. Our data suggests that intracellular UPAB1 cells egress from the macrophages. To confirm this result, we inspected the infected macrophages with UPAB1-GFP through live-video microscopy. We observed bacteria egressing the macrophages through a process that lysed the host cells (Fig 5B). Lactate dehydrogenase (LDH), a soluble cytosolic enzyme present in eukaryotic cells, is released into the culture medium upon damage to the plasma membrane[19]. The increase of LDH activity in culture supernatant is proportional to the number of damaged cells. No LDH activity was detected at 8 or 12 h p.i. However, we detected a significant increase in LDH activity in macrophages infected with UPAB1 at 24 h p.i. compared to non-infected macrophages (Fig 5C). Together, these results indicate that UPAB1 can survive and replicate inside macrophages and then escape from these cells through a lytic process. Although the mechanism for these processes will require further studies, it is tempting to speculate that UPAB1, like other bacteria that replicate and escape from the vacuole, manipulates the host cell through the activity of secreted proteins.

Fig 5. UPAB1 escapes the macrophages by a lytic process.

Fig 5

J774A.1 macrophages were infected with UPAB1. (A) At different time points, antibiotic containing medium was replaced by antibiotic-free medium. CFU in supernatants were determined and the ratio of released to intracellular bacteria was calculated. Data represent mean and standard deviation values for 3 independent experiments. (B) Images from time-lapse microscopy showing UPAB1 egress from the invaded macrophages. J774A.1 cells were infected with UPAB1 GFP (green fluorescence). At 7 h p.i. images were taken every 10 min and analyzed with ImageJ software. The white arrow indicates the infected cell. Bars: 20 μm. (C) LDH activity in the supernatant of infected macrophages was measured at 24 h p.i. Percentage of cytotoxicity was calculated as the activity of released LDH relative to total LDH activity. The mean ± S.D. for two independent experiments is shown. **** p < 0.0001.

UPAB1 replication in macrophages relies on pAB5

LCPs are a family of large conjugative plasmids present in many A. baumannii strains[20]. In previous work, we showed that pAB5, the LCP carried by UPAB1, greatly impacts virulence as its presence is required for the establishment of infection in a CAUTI model but detrimental for virulence in an acute respiratory murine model[5]. Thus, we investigated if the presence of pAB5 also impacts the ability of UPAB1 to replicate in macrophages. The strain cured of its plasmid (UPAB1p-) was unable to replicate in J774A.1 macrophages (Fig 6A), and intracellular CFUs quickly decreased after phagocytosis, indicating that UPAB1p- is efficiently eliminated by macrophages. We have previously shown that LCP controls the expression of the type VI secretion system (T6SS) [21]. We also found that pAB5 modulates the expression of other chromosomally-encoded factors. For example, pAB5 represses the synthesis of poly-N-acetyl-β-(1–6)-glucosamine (PNAG), a surface polysaccharide that plays an important role in biofilm formation in vitro, and reduces the expression of two chaperone-usher pili, CUP1 and CUP2, which are required for adhesion to fibrinogen and possibly other host receptors during infection[5]. We have recently showed that a pAB5-encoded H-NS transcriptional regulator represses the synthesis of the exopolysaccharide PNAG and other cell surface components [22]. Unlike pAB5, the closely related plasmid pAB3, does not repress PNAG synthesis [5]. Thus, to gain further insight about the roles of LCPs in UPAB1 replication, we tested the strains UPAB1 carrying pAB3 (UPAB1pAB3+) and UPAB1pAB5Δh-ns. Both strains were incapable of replicating inside J774A.1 macrophages and were quickly eliminated by the host. These results demonstrate that pAB5 enables intracellular replication of UPAB1 in a H-NS-dependent manner.

Fig 6. pAB5 and T1SS are required for UPAB1 intracellular replication.

Fig 6

(A) J774A.1 macrophages were infected with the indicated strains. UPAB1p-, UPAB1pAB3+ and UPAB1pAB5Δh-ns strains were not able to replicate. Data represents mean and standard deviation values for 3 independent experiments. *p < 0.05. (B) Genetic organization of the T1SSa and T1SSb loci. (C) Individual and double T1SS mutants have a defect in intracellular replication in J774A.1 macrophages. Data represents mean and standard deviation values, for 3 independent experiments. *p < 0.05.

Most bacteria that are able to survive and replicate inside macrophages secrete proteins via secretion systems, commonly T3SS, T4SS, T6SS, or T7SS[23]. These effectors allow the bacteria to manipulate host signaling and trafficking pathways to create a replicative niche within the macrophage. Acinetobacter spp. do not encode T3SS or T4SS, but carry T1SS, T2SS and T6SSs[24]. However, the T6SS in Acinetobacter appears to be only involved in interbacterial competition, as many recent clinical isolates do not carry a functional T6SS[18]. Our previous proteomic and RNAseq experiments showed that pAB5 increases the expression of a T1SS-secreted agglutinin RTX toxin (D1G37_00080), and an adjacently-encoded protein, OmpA[5]. This observation prompted us to investigate a possible role for the T1SS in the intracellular replication of UPAB1.

T1SS is required for UPAB1 intracellular replication

The T1SS is a highly conserved secretion system employed by pathogenic Gram-negative bacteria. This secretion machinery is composed of an ATP-binding cassette transporter anchored in the inner membrane (HlyB), a periplasmic adaptor protein (HlyD) and a third component localized in the outer membrane (TolC). Together, these elements act to facilitate the secretion of unfolded effectors from the cytoplasm to the extracellular milieu[25]. UPAB1 encodes two T1SS clusters, which we named T1SSa and T1SSb (Fig 6B). We generated ΔT1SSa, ΔT1SSb and ΔT1SSab mutant strains and analyzed their replication within macrophages. We found that all three T1SS deficient strains were unable to replicate inside J774A.1 macrophages (Fig 6C).

To identify putative T1SS-dependent effectors involved in survival and replication within macrophages, we employed a differential proteomics approach. A comparative secretome analysis between WT UPAB1 and the T1SSa and T1SSb mutant strains was performed. Table 1 lists the secreted proteins diminished in ΔT1SSa and ΔT1SSb compared to WT. We were able to identify multiple T1SS effector candidates. T1SS effectors BapA and RTX2, two common T1SS effectors, were repressed in ΔT1SSa. Neither of these proteins were repressed in ΔT1SSb, suggesting that T1SSa is the preferred secretion system employed for the export of these two proteins. Our analysis also identified additional potential T1SS effectors, including proteases, phosphatases, glycosidases, and a putative invasin (Table 1). In other bacteria, orthologs of this invasin are required to induce bacterial entry and simultaneously to block the generation of reactive oxygen species (ROS) by host monocytes and macrophages[26]. Although the identification of the T1SS effectors directly involved in intracellular replication is beyond the scope of this work, our experiments demonstrate that T1SSs play a role in the process, and our MS analysis identified several interesting candidates that will be the subject of future studies.

Table 1. Putative T1SS-dependent effectors.

T-test Difference mut_WT Locus tag Predicted function
ΔT1SSa
-10.5 D1G37_01945 BapA
-9.1 D1G37_04720 OmpA
-5.7 D1G37_05375 PilY1
-5.4 D1G37_18005 Hypothetical protein
-5.2 D1G37_15450 Phosphodiester glycosidase family protein
-5.0 D1G37_13335 Gly zipper domain/ toxic amyloid oligomer
-4.7 D1G37_05180 Secreted serine peptidase
-4.2 D1G37_05495 type IV pilus secretin PilQ
-4.0 D1G37_12590 Curli production component
-3.9 D1G37_01055 Colicin synthesis protein, bactericidal
-3.8 D1G37_10435 Bacteriocin resistance protein, peptidase
-3.8 D1G37_03120 RTX2
-3.8 D1G37_16210 Phosphatase
-3.4 D1G37_05480 Pili operon hypothetical protein
-3.3 D1G37_12980 Hypothetical protein, exported
ΔT1SSb
-9.9 D1G37_05375 PilY1
-8.0 D1G37_05445 PilA
-3.9 D1G37_04400 invasin/ igG like
-3.7 D1G37_00110 Cell surface protein Ata
-3.6 D1G37_10430 FilA
-3.4 D1G37_11695 Transferrin binding protein
-3.4 D1G37_00700 Hypothetical protein

Cut-off was defined at -3 by a student T-test difference between mutant and WT. Protein localization prediction was performed employing PSORT and presence of a signal peptide was analyzed by SignalP.

Discussion

Although intracellular survival of A. baumannii inside vacuoles has been reported, the capacity of this bacterium to replicate intracellularly has not been documented. Here, we show that modern clinical isolates, such as UPAB1, can replicate inside spacious vacuoles within macrophages. Previous reports have shown that non-replicating A. baumannii can induce autophagy in epithelial cells and macrophages and indicated that autophagy is required for clearance of intracellular bacteria[710]. TEM predominantly exhibited double-membrane enclosed vacuoles, which is indicative of an autophagic origin for the ACV. However, we found that ACVs formed by UPAB1 are LC3-negative, suggesting that these replicative ACVs do not follow a canonical autophagy pathway. It remains to be determined whether these observations are the result of LC3 degradation induced by UPAB1 or an indication that UPAB1 evades the canonical autophagy pathway before LC3 is recruited to the autophagosome. For example, in fibroblasts double membrane vacuoles can be formed without recruitment of the ATG conjugation system, leading to a complete absence of LC3 recruitment to the vacuole[27]. Moreover, intracellular pathogens manipulate the canonical host vesicular pathways, including autophagy, to create unique replicative niches[28]. The complete characterization of the replicative ACV will be the subject of future studies.

During the revision of this work, the Salcedo group reported that a subset of modern clinical isolates replicates within non-autophagic ACVs in epithelial cells[29]. In agreement with our results, large ACVs containing up to 50 bacteria were visualized in multiple non-phagocytic cells. However, some apparent differences between the ACVs formed in epithelial cells and macrophages were detected. Mainly, the replicating Acinetobacter strains were contained in single membrane vacuoles and were observed after 24 h p.i. It remains to be elucidated if these discrepancies are due to the use of different host cells and/or the particular bacterial strains tested.

Several MDR A. baumannii strains carry LCPs. These plasmids control the expression of diverse chromosomally-encoded genes. Specifically, pAB5, the LCP of UPAB1, differentially regulates the expression of various features, such as PNAG synthesis and CUP pili, directly impacting host virulence. We found that UPAB1p-, UPAB1pAB5Δh-ns, and UPAB1pAB3+ are unable to replicate within macrophages, suggesting that genetic elements regulated by pAB5 are likely involved in facilitating intracellular replication. We previously reported that pAB5 upregulates putative T1SS effectors[5]. UPAB1 carries two T1SS loci, and our data revealed that mutants in both systems are defective in intracellular replication. Although the T3SS, T4SS, and T6SS are most commonly involved in manipulation of intracellular pathways, the T1SS is involved in invasion and intracellular replication in other bacterial pathogens, such as Legionella pneumophila, Ehrlichia chaffeensis, Francisella novicida and Orientia tsutsugamushi[3033]. Our proteomic analysis identified several proteins whose secretion is significantly reduced in the individual T1SS mutants. However, since deletion of the T1SS in A. nosocomialis resulted in the downregulation of other secretion systems[34], the assignment of these proteins as T1SS effectors awaits further validation. Nevertheless, these experiments uncover several interesting, secreted proteins that may play a role in intracellular replication of UPAB1. Future work will focus on investigating these putative effectors and their possible role in the intracellular lifestyle of A. baumannii.

Depletion of macrophages enhances sepsis and severity of disease, demonstrating that macrophages play an important role in eradicating A. baumannii infection[11]. Therefore, survival and replication of A. baumannii in this type of cells may be a previously underappreciated and important feature of this bacterium. We have also shown that UPAB1 can escape the macrophages by a lytic mechanism. A. baumannii could subsequently be phagocytosed by other macrophages and re-start the infection process. Thus, we propose that by replicating inside vacuoles in macrophages, A. baumannii evades the immune response and disseminates, resulting in hypervirulent phenotypes. Furthermore, it is tempting to speculate that antibiotics cannot reach the lumen of the ACV, which may contribute to tolerance of A. baumannii to antibiotics. Identifying the bacterial factors involved in the intracellular cycle of MDR A. baumannii may enable the design of new therapies to combat this pathogen.

Materials and methods

Bacterial strains and culture conditions

The bacterial strains used in this study are listed in S1 Table. Unless otherwise noted, strains were grown in lysogeny broth (LB) liquid medium under shaking conditions (200 rpm), or in LB-agar at 37°C. When required, antibiotics were used at the following concentrations: zeocin 50 μg/ml, kanamycin 30 μg/ml, gentamicin 15 μg/ml, and chloramphenicol 15 μg/ml.

DNA manipulation

DNA manipulations were performed according to standard techniques. PCR reactions were performed using Phusion High Fidelity DNA polymerase (New England Biolabs), according to the manufacturer’s instructions. Genetic manipulations were carried out in Escherichia coli Stellar competent cells (Clontech). Primers and plasmids used in this study are listed in S2 and S3 Tables, respectively.

The gfp gene was PCR amplified from pBAV1K-t5-gfp[35] and cloned into pUC18T-mini-Tn7T-Zeo by In-Fusion Cloning (Takara). The pUC18T-mini-Tn7T-Zeo-GFP vector was conjugated to Acinetobacter as previously described[36]. All transconjugant strains were confirmed by PCR analysis and fluorescence microscopy.

Construction of A. baumannii mutant strains

Mutants were constructed as described previously[37]. Briefly, a FRT site-flanked zeocin resistance cassette was amplified from a variant of pKD4[38] with primers harboring 18–25 nucleotides of homology to the flanking regions of the targeted gene to delete. Upstream and downstream flanking regions were also amplified, and fragments were assembled by overlap extension PCR. This PCR product was electroporated into competent UPAB1 carrying pAT04, which expresses the RecAB recombinase[37]. Mutants were selected with zeocin, and integration of the resistance marker was confirmed by PCR. To remove the zeocin resistance cassette, electrocompetent mutants were transformed with pAT03 plasmid, which expresses the FLP recombinase. Zeocin-sensitive clones of clean deletion mutants were obtained. All mutant strains were confirmed by antibiotic resistance profile, PCR, and sequencing.

Cell culture conditions

J774A.1 (ATCC TIB-67) mouse macrophage cell line was cultured in Dulbecco’s Modified Eagle Medium (DMEM) High Glucose (Hyclone, SH30022.01) supplemented with 10% inactivated Fetal Bovine Serum (FBS, Corning) at 37°C and 5% CO2. THP-1 (ATCC TIB-202) human monocyte cell line was cultured in RPMI-1640 medium (Sigma, R8758) supplemented with 10% FBS, 0.01% MEM Non-Essential Amino Acids (Corning, 25-025-Cl), and 50 μM 2-mercaptoethanol at 37°C and 5% CO2. For the infection experiments, the THP-1 monocytes were differentiated to macrophages by supplementing the medium with 40 ng/ml of phorbol 12-myristate 13-acetate (PMA, AdipoGen Life Sciences) 48 h prior to the infection.

The bone marrow derived macrophages (BMDM) were obtained from wild-type BALB/c mice as described previously[39] and cultured in DMEM supplemented with 10% FBS at 37°C and 5% CO2. For the infection experiments, the BMDM were incubated with 10 ng/ml γ-INF overnight prior to the infection.

Antibiotic protection assay

For the intracellular replication assays, J774A.1 cells were cultured in 48 well plates 12–16 h before the experiment (3x105 cells/well). A. baumannii strains were grown overnight in LB at 37°C under shaking conditions. Bacterial cultures were normalized to OD600 = 1, washed once with PBS, and an appropriate volume was added to each well to reach an MOI of 10. Plates were centrifuged 10 min at 200 x g and incubated for 1 h at 37°C and 5% CO2. Cells were washed three times with PBS and subsequently incubated with medium supplemented with 100 μg/ml gentamicin and 400 μg/ml kanamycin to kill extracellular bacteria. At 2 h post infection (p.i.) the concentration of antibiotics was decreased to 30 μg/ml gentamicin and 200 μg/ml kanamycin. At 2, 4, 6, and 8 h p.i., cells were washed and lysed with 0.1% Triton X-100. Colony forming units (CFUs) were determined by serial dilution.

To determine the number of bacteria that egress from the infected cells, the antibiotic containing medium was replaced with antibiotic-free medium. At the indicated time points and after 20 min incubation, the supernatant was recovered and serially diluted to determine CFU. The ratio of released bacteria in relation to the number of intracellular bacteria corresponding to each time point was then calculated.

Immunofluorescence staining

For LC3B staining, samples were fixed with ice cold 100% methanol for 5 min at room temperature, permeabilized with 1% saponin for 20 min, and blocked with 1% PBS-BSA for 1 h. The glass cover slips were incubated with the primary antibody rabbit anti-LC3 (Sigma) at a 1:100 dilution for 3 h at room temperature, then washed 3 times with 1X PBS and incubated with the secondary antibody goat anti-rabbit Alexa 594 (Invitrogen) at a 1:100 dilution and DAPI for 1 h at room temperature. Afterwards, samples were washed with PBS and mounted with ProLong Glass Antifade Mountant solution (Invitrogen).

Confocal microscopy

Infected cells were analyzed with a Zeiss LSM880 laser scanning confocal microscope (Carl Zeiss Inc.) equipped with 405nm diode, 488nm Argon, 543nm HeNe, and 633nm HeNe lasers. A Plan-Apochromat 63X (NA 1.4) DIC objective and ZEN black 2.1 SP3 software were used for image acquisition.

Live imaging

8x105 J774A.1 cells were plated in a 10 mm Glass Bottom Culture 35 mm petridish (MATEK corporation, P35G-0-14-C) 12–16 h prior to the infection. On the following day, a gentamicin-kanamycin protection assay was performed using UPAB1 GFP at an MOI = 10 as described above. At 2 h p.i., cells were incubated in DMEM without phenol red (Hyclone) supplemented with 10% FBS, 30 μg/ml gentamicin, and 200 μg/ml kanamycin. Imaging started at 3.5 h p.i. and pictures were taken every 10 or 20 min.

Time lapse microscopy

Live images were acquired on a Zeiss Observer Z1 inverted microscope equipped with a temperature-controlled CO2 incubation chamber. Fluorescence images were acquired with illumination from a Colibri 7 LED light source (Zeiss) and ORCA-ER digital camera (Hammamatsu Photonics, Japan). A Plan-Apochromat 63X (NA 1.4) Phase 3 objective and ZEN blue 2.5 software were used for image acquisition.

Transmission electron microscopy

For the Transmission Electron Microscopy (TEM) assay, J774A.1 cells were cultured in 24 well plates 12–16 h before the experiment (2.5x105 cells/well). The next day, an antibiotic protection assay was performed using UPAB1 GFP at an MOI = 10. At 4, 5, and 7 h p.i., the cells were washed, detached with a scraper, and pooled together. Cells were fixed in 2% paraformaldehyde/2.5% glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM sodium cacodylate buffer pH 7.2 for 1 h at room temperature and subsequently transferred to 4°C overnight. Samples were washed in sodium cacodylate buffer at room temperature and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 h. Samples were then rinsed extensively in distilled water prior to bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 h. Following several rinses in distilled water, samples were dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA).

Cytotoxicity assay

Lactate dehydrogenase (LDH) activity was measure with the CytoTox-One Homogeneous Membrane Integrity Assay kit (Promega), according to the manufacturer directions. Enzymatic activity, as a signal of damage of plasma membrane, was measured from the supernatants of infected cells at 8, 12 and 24 h p.i. Non-infected cells were included as a negative control, and cells treated with 0.1% Triton X-100 were the 100% lysis control.

Secreted protein enrichment for quantitative proteomics analysis

UPAB1 and derivative strains were grown overnight in 5 ml of M9 minimal medium supplemented with 0.2% casamino acids (M9CAA) and subsequently diluted to OD600 = 0.05 in 100 ml of fresh M9CAA. Cultures were incubated to mid-log phase and centrifuged at 15,000 x g for 2 min. Supernatants were filter-sterilized with Steriflip vacuum-driven filtration devices (Millipore), concentrated with an Amicon Ultra (Millipore) concentrator with a 10-kDa molecular weight cutoff, flash frozen, and lyophilized. Lyophilized samples were then processed for mass spectrometry analysis as described below. Four individual 100-ml culture biological replicates were prepared for each strain.

Digestion of secretome samples

Precipitated secretomes were resuspended in 6 M urea and 2 M thiourea with 40 mM NH4HCO3 and then reduced for 1 h with 20 mM DTT. Reduced samples were then alkylated with 50 mM iodoacetamide for 1 h in the dark. The alkylation reaction was then quenched by the addition of 50 mM DTT for 15 min, and samples were digested with Lys-C (1/200 w/w) for 3 h at room temperature. Samples were diluted with 100 mM NH4HCO3 four-fold to reduce the urea/thiourea concentration below 2M, and then an overnight trypsin (1/50 w/w) digestion was performed at room temperature. Digested samples were acidified to a final concentration of 0.5% formic acid and desalted with home-made high-capacity StageTips composed of 1 mg Empore C18 material (3M) and 5 mg of OLIGO R3 reverse phase resin (Thermo Fisher Scientific) as previously described [40,41]. Columns were wet with Buffer B (0.1% formic acid, 80% acetonitrile) and conditioned with Buffer A* (0.1% TFA, 2% acetonitrile) prior to use. Acidified samples were loaded onto conditioned columns, washed with 10 bed volumes of Buffer A*, and bound peptides were eluted with Buffer B before being dried then stored at -20°C.

LC-MS analysis of secretome samples

Dried secretome digests were re-suspended in Buffer A* and separated using a two-column chromatography set up composed of a PepMap100 C18 20 mm x 75 μm trap and a PepMap C18 500 mm x 75 μm analytical column (Thermo Fisher Scientific). Samples were concentrated onto the trap column at 5 μl/min for 5 min with Buffer A (0.1% formic acid, 2% DMSO) and then infused into an Orbitrap Q-Exactive plus Mass Spectrometer (Thermo Fisher Scientific) at 300 nl/min via the analytical column using a Dionex Ultimate 3000 UPLC (Thermo Fisher Scientific). 125-min analytical runs were undertaken by altering the buffer composition from 2% (0.1% formic acid, 77.9% acetonitrile, 2% DMSO) to 22% Buffer B over 95 min, then from 22% to 40% Buffer B over 10 min, and 40% to 80% Buffer B over 5 min. The composition was held at 80% Buffer B for 5 min and then dropped to 2% over 2 min before being held at 2% for another 8 min. The Q-Exactive plus Mass Spectrometer was operated in a data-dependent mode automatically switching between the acquisition of a single Orbitrap MS scan (375–1400 m/z, maximal injection time of 50 ms, an Automated Gain Control (AGC) set to a maximum of 3*106 ions, and a resolution of 70k) and up to 15 Orbitrap MS/MS HCD scans of precursors (Stepped NCE of 28%, 30% and 35%, a maximal injection time of 100 ms, an AGC set to a maximum of 2*105 ions, and a resolution of 17.5k).

Proteomic analysis

Secretome samples were processed using MaxQuant (v1.6.17.0.[42]) and searched against the NCBI annotated A. baumannii UPAB1 proteome (NCBI Accession: PRJNA487603, 3750 proteins, downloaded 2020-3-10), a six-frame translation of the UPAB1 genome generated using the six-frame translation generator within Maxquant, and the ATCC17978 proteome (Uniprot: UP000319385, 3627 proteins, downloaded 2014-11-16) to allow the use of Uniprot annotation information associated with ATCC17978 proteins. Searches were undertaken using “Trypsin” enzyme specificity with carbamidomethylation of cysteine as a fixed modification. Oxidation of methionine and acetylation of protein N-termini were included as variable modifications, and a maximum of 2 missed cleavages were allowed. To enhance the identification of peptides between samples, the Match between Runs option was enabled with a precursor match window set to 2 min and an alignment window of 20 min with the label free quantitation (LFQ) option enabled[43]. The resulting outputs were processed within the Perseus (v1.6.0.7) analysis environment[44] to remove reverse matches and common protein contaminates prior to further analysis. For LFQ comparisons, biological replicates were grouped and data was filtered to remove any protein which was not observed in at least one group three times. Missing values were then imputed based on the observed total peptide intensities with a range of 0.3σ and a downshift of 2.5σ using Perseus. Student t tests were undertaken to compare the secretome between groups with the resulting data exported and visualized using ggplot2[45] within R. The resulting MS data and search results have been deposited into the PRIDE ProteomeXchange Consortium repository[46,47] and can be accessed with the identifier:PXD024736 using the Username: reviewer_pxd024736@ebi.ac.uk and Password: YS5qjHcG.

Statistical analysis

All statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software Inc., La Jolla, CA). For all datasets, Student’s unpaired t-tests were used.

Supporting information

S1 Fig. UPAB1 but not 19606 replicates in macrophages.

Representative images of infected cells at the indicated time points. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Individual channels (greyscale) and merged images are shown. Bars: 20 μm.

(TIF)

S2 Fig. UPAB1 replicates in multiple host cell lines.

Representative Z-projections with orthogonal views of infected J774A.1 cells (left panel) or BMDM (right panel) at 7 and 5 h p.i., respectively. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Bars: 20 μm. White arrows indicate the vacuole.

(TIF)

S3 Fig. UPAB1 ACVs are LC3 negative.

Representative images of J774A.1 macrophages (A) non-infected, (B) Serratia marcescens-infected (2 h p.i.), or (C) UPAB1-infected (1, 2.5 and 5 h p.i.). Samples were stained for cell nuclei (grey), LC3 (magenta) and bacteria expressing GFP (cyan). Individual channels (greyscale) and merged images are shown. Insets show a higher magnification of the area indicated by the white box. Bars: 20 μm.

(TIF)

S4 Fig. UPAB1 replicates in multiple host cell lines.

Representative images of infected THP-1 (upper panels) or BMDM (lower panels) cells at 5 h p.i. Samples were stained for cell nuclei (grey), actin (magenta) and UPAB1 GFP (cyan). Individual channels (greyscale) and merged images are shown. Bars: 20 μm.

(TIF)

S5 Fig. Recent clinical isolates replicate in J774A.1 macrophages.

Representative images of infected cells with the indicated strains. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Individual channels (greyscale) and merged images are shown. Bars: 20 μm.

(TIF)

S1 Table. Bacterial strains used in this study.

(DOCX)

S2 Table. Primers used in this study.

(DOCX)

S3 Table. Plasmids used in this study.

(DOCX)

S1 Dataset. Data used in this study.

(XLSX)

Acknowledgments

We thank the imaging laboratory of the Molecular Microbiology Department at Washington University in St Louis. We thank Dr. Rachel L. Kinsella for kindly providing BMDM. We thank the members of the Feldman lab for critical reading of the manuscript.

Data Availability

The authors declare that data supporting the findings of this study are available within the paper and its supplemental files (Data set S1). The resulting MS data and search results have been deposited into the PRIDE ProteomeXchange Consortium repository[47,48] and can be accessed with the identifier PXD024736 using the Username: reviewer_pxd024736@ebi.ac.uk and Password: YS5qjHcG.

Funding Statement

MFF was supported by grants from the National Institute of Allergy and Infectious Diseases (grant R01AI144120). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37: 1288–1301. doi: 10.1017/ice.2016.174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Valencia R, Arroyo LA, Conde M, Aldana JM, Torres M-J, Fernández-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009;30: 257–63. doi: 10.1086/595977 [DOI] [PubMed] [Google Scholar]
  • 3.Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global Priority List of Antibiotic-Resistant Bacteria To Guide Research, Discovery, and Development of New Antibiotics. 2017.
  • 4.Centers for Disease Control U. Antibiotic Resistance Threats in the United States, 2019. [cited 8 Apr 2021]. doi: 10.15620/cdc:82532 [DOI]
  • 5.Di Venanzio G, Flores-Mireles AL, Calix JJ, Haurat MF, Scott NE, Palmer LD, et al. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic Acinetobacter baumannii chromosomal genes. Nat Commun. 2019;10: 1100. doi: 10.1038/s41467-019-08917-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kinsella RL, Lopez J, Palmer LD, Salinas ND, Skaar EP, Tolia NH, et al. Defining the interaction of the protease CpaA with its type II secretion-chaperone CpaB and its contribution to virulence in Acinetobacter species. 2017. doi: 10.1074/jbc.M117.808394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.An Z, Huang X, Zheng C, Ding W. Acinetobacter baumannii outer membrane protein A induces HeLa cell autophagy via MAPK/JNK signaling pathway. Int J Med Microbiol. 2018. [cited 15 Jan 2019]. doi: 10.1016/j.ijmm.2018.12.004 [DOI] [PubMed] [Google Scholar]
  • 8.Wang Y, Zhang K, Shi X, Wang C, Wang F, Fan J, et al. Critical role of bacterial isochorismatase in the autophagic process induced by Acinetobacter baumannii in mammalian cells. FASEB J. 2016; 1–15. doi: 10.1096/fj.16-0101ufm [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bist P, Dikshit N, Koh TH, Mortellaro A, Tan TT, Sukumaran B. The Nod1, Nod2, and Rip2 Axis Contributes to Host Immune Defense against Intracellular Acinetobacter baumannii Infection. Infect Immun. 2014;82: 1112–1122. doi: 10.1128/IAI.01459-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Parra-Millán R, Guerrero-Gómez D, Ayerbe-Algaba R, Pachón-Ibáñez ME, Miranda-Vizuete A, Pachón J, et al. Intracellular Trafficking and Persistence of Acinetobacter baumannii Requires Transcription Factor EB. mSphere. 2018;3: e00106–18. doi: 10.1128/mSphere.00106-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Grguric-Smith LM, Lee HH, Gandhi JA, Brennan MB, DeLeon-Rodriguez CM, Coelho C, et al. Neutropenia exacerbates infection by Acinetobacter baumannii clinical isolates in a murine wound model. Front Microbiol. 2015;6: 1134. doi: 10.3389/fmicb.2015.01134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rumbo C, Tomás M, Moreira EF, Soares NC, Carvajal M, Santillana E, et al. The Acinetobacter baumannii Omp33-36 porin is a virulence factor that induces apoptosis and modulates autophagy in human cells. Infect Immun. 2014;82: 4666–4680. doi: 10.1128/IAI.02034-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Nakagawa I, Amano A, Mizushima N, Yamamoto A, Yamaguchi H, Kamimoto T, et al. Autophagy defends cells against invading group A Streptococcus. Science (80-). 2004;306: 1037–1040. doi: 10.1126/science.1103966 [DOI] [PubMed] [Google Scholar]
  • 14.Fedrigo G V, Campoy EM, Di Venanzio G, Colombo MI, García Véscovi E. Serratia marcescens Is Able to Survive and Proliferate in Autophagic-Like Vacuoles inside Non-Phagocytic Cells. May RC, editor. PLoS One. 2011;6: 15. doi: 10.1371/journal.pone.0024054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Romano PS, Gutierrez MG, Berón W, Rabinovitch M, Colombo MI. The autophagic pathway is actively modulated by phase II Coxiella burnetii to efficiently replicate in the host cell. Cell Microbiol. 2007;9: 891–909. doi: 10.1111/j.1462-5822.2006.00838.x [DOI] [PubMed] [Google Scholar]
  • 16.Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19: 5720–8. doi: 10.1093/emboj/19.21.5720 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, et al. AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments. MBio. 2014;5: 1–10. doi: 10.1128/mBio.01076-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lopez J, Ly PM, Feldman MF. The tip of the VgrG spike is essential to functional type VI secretion system assembly in acinetobacter baumannii. MBio. 2020;11: 1–14. doi: 10.1128/mBio.02761-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. 2018;2018: 465–468. doi: 10.1101/pdb.prot095497 [DOI] [PubMed] [Google Scholar]
  • 20.Di Venanzio G, Moon KH, Weber BS, Lopez J, Ly PM, Potter RF, et al. Multi-drug resistant plasmids repress T6SS to enable their dissemination. Proc Natl Acad Sci U S A. 2019;116: 1–23. doi: 10.1073/pnas.1812557116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Weber BS, Ly PM, Irwin JN, Pukatzki S, Feldman MF. A multidrug resistance plasmid contains the molecular switch for type VI secretion in Acinetobacter baumannii. Proc Natl Acad Sci U S A. 2015;112: 9442–7. doi: 10.1073/pnas.1502966112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Benomar S, Di Venanzio G, Feldman MF. Plasmid-encoded H-NS controls extracellular matrix composition in a modern Acinetobacter baumannii urinary isolate. bioRxiv. 2021; 2021.05.19.444899. doi: 10.1101/2021.05.19.444899 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Costa TRD, Felisberto-Rodrigues C, Meir A, Prevost MS, Redzej A, Trokter M, et al. Secretion systems in Gram-negative bacteria: structural and mechanistic insights. Nat Rev Microbiol. 2015;13: 343–359. doi: 10.1038/nrmicro3456 [DOI] [PubMed] [Google Scholar]
  • 24.Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2017;16: 91–102. doi: 10.1038/nrmicro.2017.148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Thomas S, Holland IB, Schmitt L. The Type 1 secretion pathway—The hemolysin system and beyond. Biochimica et Biophysica Acta—Molecular Cell Research. Elsevier; 2014. pp. 1629–1641. doi: 10.1016/j.bbamcr.2013.09.017 [DOI] [PubMed] [Google Scholar]
  • 26.Teymournejad O, Rikihisa Y. Ehrlichia chaffeensis uses an invasin to suppress reactive oxygen species generation by macrophages via cd147-dependent inhibition of vav1 to block rac1 activation. MBio. 2020;11. doi: 10.1128/mBio.00267-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tsuboyama K, Koyama-Honda I, Sakamaki Y, Koike M, Morishita H, Mizushima N. The ATG conjugation systems are important for degradation of the inner autophagosomal membrane. Science (80-). 2016;354: 1036–1041. doi: 10.1126/science.aaf6136 [DOI] [PubMed] [Google Scholar]
  • 28.Kimmey JM, Stallings CL. Bacterial Pathogens versus Autophagy: Implications for Therapeutic Interventions. Trends in Molecular Medicine. Elsevier Ltd; 2016. pp. 1060–1076. doi: 10.1016/j.molmed.2016.10.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rubio T, Gagné S, Debruyne C, Dias C, Cluzel C, Mongellaz D, et al. Incidence of an intracellular multiplication niche amongst Acinetobacter baumannii clinical isolates. bioRxiv. 2021; 2021.04.15.439986. doi: 10.1101/2021.04.15.439986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Saha SS, Uda A, Watanabe K, Shimizu T, Watarai M. RtxA like protein contributes to infection of Francisella novicida in silkworm and human macrophage THP-1. Microb Pathog. 2018;123: 74–81. doi: 10.1016/j.micpath.2018.06.046 [DOI] [PubMed] [Google Scholar]
  • 31.Fuche F, Vianney A, Andrea C, Doublet P, Gilbert C. Functional type 1 secretion system involved in Legionella pneumophila virulence. J Bacteriol. 2015;197: 563–571. doi: 10.1128/JB.02164-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Luo T, McBride JW. Ehrlichia chaffeensis TRP32 interacts with host cell targets that influence intracellular survival. Infect Immun. 2012;80: 2297–2306. doi: 10.1128/IAI.00154-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.VieBrock L, Evans SM, Beyer AR, Larson CL, Beare PA, Ge H, et al. Orientia tsutsugamushi ankyrin repeat-containing protein family members are type 1 secretion system substrates that traffic to the host cell endoplasmic reticulum. Front Cell Infect Microbiol. 2014;4. doi: 10.3389/fcimb.2014.00004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Harding CM, Pulido MR, Di Venanzio G, Kinsella RL, Webb AI, Scott NE, et al. Pathogenic Acinetobacter species have a functional type i secretion system and contact-dependent inhibition systems. J Biol Chem. 2017;292. doi: 10.1074/jbc.M116.763268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Bryksin A V., Matsumura I. Rational Design of a Plasmid Origin That Replicates Efficiently in Both Gram-Positive and Gram-Negative Bacteria. Mokrousov I, editor. PLoS One. 2010;5: e13244. doi: 10.1371/journal.pone.0013244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ducas-Mowchun K, De Silva PM, Crisostomo L, Fernando DM, Chao TC, Pelka P, et al. Next generation of Tn7-based single-copy insertion elements for use in multi- and pan-drug-resistant strains of Acinetobacter baumannii. Appl Environ Microbiol. 2019;85. doi: 10.1128/AEM.00066-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tucker AT, Nowicki EM, Boll JM, Knauf GA, Burdis NC, Trent MS, et al. Defining gene-phenotype relationships in Acinetobacter baumannii through one-step chromosomal gene inactivation. MBio. 2014;5: e01313–e01314. doi: 10.1128/mBio.01313-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hashim S, Mukherjee K, Raje M, Basu SK, Mukhopadhyay a. Live Salmonella modulate expression of Rab proteins to persist in a specialized compartment and escape transport to lysosomes. J Biol Chem. 2000;275: 16281–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/10821869 doi: 10.1074/jbc.275.21.16281 [DOI] [PubMed] [Google Scholar]
  • 39.Kimmey JM, Huynh JP, Weiss LA, Park S, Kambal A, Debnath J, et al. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature. 2015;528: 565–569. doi: 10.1038/nature16451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ishihama Y, Rappsilber J, Mann M. Modular stop and go extraction tips with stacked disks for parallel and multidimensional Peptide fractionation in proteomics. J Proteome Res. 2006;5: 988–94. doi: 10.1021/pr050385q [DOI] [PubMed] [Google Scholar]
  • 41.Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2007;2: 1896–906. doi: 10.1038/nprot.2007.261 [DOI] [PubMed] [Google Scholar]
  • 42.Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26: 1367–1372. doi: 10.1038/nbt.1511 [DOI] [PubMed] [Google Scholar]
  • 43.Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014;13: 2513–26. doi: 10.1074/mcp.M113.031591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13: 731–40. doi: 10.1038/nmeth.3901 [DOI] [PubMed] [Google Scholar]
  • 45.Wickham H. ggplot2—Elegant Graphics for Data Analysis |. New York: Springer-Verlag; 2016. Available: https://www.springer.com/gp/book/9783319242750 [Google Scholar]
  • 46.Vizcaíno JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44: D447–D456. doi: 10.1093/nar/gkv1145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 2019;47: D442–D450. doi: 10.1093/nar/gky1106 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Denise M Monack, David S Weiss

2 May 2021

Dear Dr Feldman,

Thank you very much for submitting your manuscript "Modern Acinetobacter baumannii clinical isolates replicate inside spacious vacuoles and egress from macrophages" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

David S. Weiss

Associate Editor

PLOS Pathogens

Denise Monack

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: In this manuscript, Sycz and colleagues describe a phenomenon in which several Acinetobacter baumannii clinical isolates (such as UPAB1), unlike common laboratory stains, replicate in the vacuoles of macrophages and eventually lead to lytic cell death. The intracellular survival of UPAB1 relies on a large conjugative plasmid (pAB5) and its type I secretion system (T1SS) regulated by pAB5. The study is quite straightforward and the conclusion is justified. The importance of this study is that it urges the field to focus on the clinical stain as it clearly differs from the long and commonly used laboratory strain in the virulence and intracellular trafficking properties. The observations reported in this study will serve as a good foundation for the field to further analyze the pathogenesis mechanism of Acinetobacter baumannii, which is more relevant to understand the real-world infections caused by this important pathogen. However, the study is still of descriptive nature and lacks in-depth insights into the mechanism underlying the unique intracellular life cycle of the new Acinetobacter baumannii strain.

Reviewer #2: In this manuscript, Feldmann and colleagues demonstrate that Acinetobacter baumannii can survive intracellularly in macrophages. Previous studies with A. baumannii had largely focused on a 19606, a urinary isolate obtained in 1967. This strain does not survive in macrophages, which led to the idea that A. baumannii is an "extracellular opportunistic pathogen". The findings reported here turn this idea upside down! The manuscript is very well-written, the experiments easy to follow and the conclusions are justified. Only minor weaknesses were noted, specifically in figure presentation and lack of clarity about the prevalence of the intracellular replication phenotype amongst A. baumannii isolates.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: 1. I am not convinced that half of the vacuoles surrounding Acinetobacter baumannii UPAB1 have double-membrane structures, according to the right panel of Fig 1B. The lipid bilayer shown in this panel does not seem to tell the difference between the left and the right panel. More convincing data, including appropriate controls and statistics are needed to conclude this point. Also, the logic flow is a little strange. Examination of the LC3 marker on the ACVs should follow immediately after the discovery of the double-membrane structure, rather than follows the description of bacterial CFU in different macrophages. The authors should address what is the nature of the double-membrane structure as it is counterintuitively LC3-negative.

2. Which kind of lytic cell death is induced by UPAB? Markers of different cell-death types should be checked. Further, what about other clinical strains and the UPAB strain lacking pAB5 or T1SS, and do they induce similar lytic cell death? It is reasonable to speculate that the decrease in CFU of 19606 or pAB5-deficient UPAB may be due to the faster lytic death of macrophages. Therefore, more details and mechanisms should be provided.

3. Give more information about the LCP plasmid. In addition to transcriptional regulation, are there other genes involved in bacterial virulence? What are the key transcription factors? Could the macrophage replicating phenotype be reconstituted in 19606 by putting back the pAB5 plasmid?

4. A key aspect of this study is to explore the mechanism of UPAB replication in macrophages. However, data addressing this question are weak and not sufficient. More insights into the mechanism should be provided.

5. How about the life cycle of the different A. baumannii strains in epithelial cells? Is that similar to macrophages?

Reviewer #2: (No Response)

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response)

Reviewer #2: (1) In Figure 2 and Figure 4, the authors show that UPAB1, 286, 398, 413 and 414 isolates are all capable of limited replication in J774A.1 macrophages. Therefore all recent clinical isolates tested here are capable of replicating inside macrophages. How representative is this phenomenon? Are there recent clinical isolates that were not able to survive and replicate for example?

(2) The confocal images do not do the findings any justice. They are too small and it is difficult to see any detail. PLOS Pathogens does not have a page limit - please make them larger. Also individual channels should be shown in greyscale, as well as an overlay of the individual channels. See a number of articles on how to present fluorescence microscopy images for color blind readers and to improve clarity.

https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001161

https://www.molbiolcell.org/doi/10.1091/mbc.e11-09-0824

(3) Lines 48-51. Reference required.

(4) Line 121. Pertaining to Figure S2C. Two representative images are shown from 5 h p.i. and none from 1 h p.i. Please include an image of the early timepoint for comparison.

(5) Figure 5C. Why was LDH release not measured until 24 h p.i.? Bacterial release occurs at 5-8 h p.i., which should be coincident with LDH release. Please include LDH release data for earlier timepoints, or explain in the text why it was not done at earlier timepoints.

(6) Line 204. The Salcedo lab has recently reported similar findings in epithelial cells on BioRXiv. Please cite this article rather than "personal communication".

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Denise M Monack, David S Weiss

14 Jul 2021

Dear Dr Feldman,

We are pleased to inform you that your manuscript 'Modern Acinetobacter baumannii clinical isolates replicate inside spacious vacuoles and egress from macrophages' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

David S. Weiss

Associate Editor

PLOS Pathogens

Denise Monack

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Denise M Monack, David S Weiss

5 Aug 2021

Dear Dr Feldman,

We are delighted to inform you that your manuscript, "Modern Acinetobacter baumannii clinical isolates replicate inside spacious vacuoles and egress from macrophages," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. UPAB1 but not 19606 replicates in macrophages.

    Representative images of infected cells at the indicated time points. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Individual channels (greyscale) and merged images are shown. Bars: 20 μm.

    (TIF)

    S2 Fig. UPAB1 replicates in multiple host cell lines.

    Representative Z-projections with orthogonal views of infected J774A.1 cells (left panel) or BMDM (right panel) at 7 and 5 h p.i., respectively. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Bars: 20 μm. White arrows indicate the vacuole.

    (TIF)

    S3 Fig. UPAB1 ACVs are LC3 negative.

    Representative images of J774A.1 macrophages (A) non-infected, (B) Serratia marcescens-infected (2 h p.i.), or (C) UPAB1-infected (1, 2.5 and 5 h p.i.). Samples were stained for cell nuclei (grey), LC3 (magenta) and bacteria expressing GFP (cyan). Individual channels (greyscale) and merged images are shown. Insets show a higher magnification of the area indicated by the white box. Bars: 20 μm.

    (TIF)

    S4 Fig. UPAB1 replicates in multiple host cell lines.

    Representative images of infected THP-1 (upper panels) or BMDM (lower panels) cells at 5 h p.i. Samples were stained for cell nuclei (grey), actin (magenta) and UPAB1 GFP (cyan). Individual channels (greyscale) and merged images are shown. Bars: 20 μm.

    (TIF)

    S5 Fig. Recent clinical isolates replicate in J774A.1 macrophages.

    Representative images of infected cells with the indicated strains. Samples were stained for cell nuclei (grey), actin (magenta) and Acinetobacter GFP (cyan). Individual channels (greyscale) and merged images are shown. Bars: 20 μm.

    (TIF)

    S1 Table. Bacterial strains used in this study.

    (DOCX)

    S2 Table. Primers used in this study.

    (DOCX)

    S3 Table. Plasmids used in this study.

    (DOCX)

    S1 Dataset. Data used in this study.

    (XLSX)

    Attachment

    Submitted filename: Cover letter.docx

    Data Availability Statement

    The authors declare that data supporting the findings of this study are available within the paper and its supplemental files (Data set S1). The resulting MS data and search results have been deposited into the PRIDE ProteomeXchange Consortium repository[47,48] and can be accessed with the identifier PXD024736 using the Username: reviewer_pxd024736@ebi.ac.uk and Password: YS5qjHcG.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES